Cystic Fibrosis Foundation - Click here for homepage
Stay Informed  |  Volunteer  |  Clinical Trials

In This Section

Quick Links

Find a Chapter

Get Assistance

Get Assistance - Cox Boys
We are here to help people with CF get the insurance coverage they need. Hear how the Foundation helped the Cox family.

Join us on Facebook!  Facebook 
Follow us on Twitter!   Twitter
Follow us on Instagram!  Instagram 
Add us to your circle in Google+!

Google+ 

Subscribe to our channel on YouTube!  YouTube  


 

 

Bookmark and Share   Print  

FDA Advisory Committee Backs New Form of CF Drug
 
September 7, 2012
 
A U.S. Food and Drug Administration outside advisory panel has backed a new form of the CF drug TOBI® (tobramycin solution for inhalation).
 
The panel of advisers voted 13 to 1 that Novartis, the drug’s manufacturer, had demonstrated that its tobramycin inhalation powder (TIP), was safe and effective for the treatment of CF patients whose lungs contain Pseudomonas aeruginosa. This bacteria is the leading cause of lung damage in cystic fibrosis patients.

TIP can be taken with an inhaler, making it a convenient alternative to the older version of the drug, TOBI, which must be taken using a nebulizer. Novartis is seeking approval of the antibiotic powder.
 
Read the story from Reuters news service.

The Cystic Fibrosis Foundation is an accredited charity of the Better Business Bureau.